February 5, 2025 8:02am

If you own, keep it; any negative catalyst could be especially impactful in the sector for only so long

Earnings dates: ALNY, MRNA, SAGE and IONS <in the Bottom Line>

To watch more insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninform

VIP: I will be partially unavailable in the week 2/3 – 2/7/25 due my “better half or the babe” underwent successful surgery yet will continue to be hospitalized – say a prayer please!

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Tuesday’s night’s … RegMed Investors (RMi) Closing Bell: follow the bouncing share pricing … https://www.regmedinvestors.com/articles/13791

 

Wednesday; the pre-open Dow futures are DOWN -0.11% or (-51 points), the S&P futures are DOWN -0.42% or (-25 points) and the Nasdaq futures are DOWN -0.76% or (-165 points)

  • Stock futures fell Wednesday,
  • European markets traded in mixed territory,
  • Asia-Pacific markets mostly rise

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed UP +134.13 points or +0.30%, the S&P closed UP +43.31 points or +0.72% while the Nasdaq closed UP +262.06 points or +1.35%

Economic Data Docket: The Job Openings and Labor Turnover Survey for December as well as durable orders

 

Q1/25: February – 1 negative and 1 positive closes

  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • There is NO forecast … didn’t looking good in aftermarket or pre-open …
  • Better part of valor to not lead any investor to temptation; yet again … I am AGAIN passing on forecasting the daily indications as to Tuesday while the aftermarket fluctuated and the pre-open waits for the open …  it is still a mix of ups, downs and just unknowns.
  • NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

 

The BOTTOM LINE: prepare for more market volatility related to trade uncertainty and upcoming sector earnings

February ‘25: understand the “flow” …

  • 2/4 - Tuesday ended with a positive close at the close of 24 incliner, 9 decliners and 2 flats
  • 2/3 – Monday - ended with a negative close at the close of 8 incliner, 25 decliners and 2 flats

 

Earnings are a-comin’ … from Q4/24 are due …  keep an eye on your portfolio!

  • Sage Therapeutics (SAGE) Tuesday, 2/11
  • Alnylam Pharmaceuticals (ALNY) – Thursday, 2/13
  • Moderna (MRNA) –– 2/14, Friday
  • Ionis Pharmaceuticals (IONS) -Wednesday, 2/19

 

What could 2025 have in store for the capital access space as Partners are the gift of life!

  • "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.